Infectious causes of cancer

United States Hepatitis B Market Report 2019: Analysis & Outlook Through 2014-2024 - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 11, 2019
Health, Pharmaceutical, Medical specialties, Infectious diseases, Medicine, RTT, Infectious causes of cancer, Hepatitis, World Hepatitis Day

US Hepatitis B Market and Competitive Landscape Highlights - 2019, provides comprehensive insights into Hepatitis B pipeline products, Hepatitis B epidemiology, Hepatitis B market valuations and forecast, Hepatitis B drugs sales and competitive landscape in the US.

Key Points: 
  • US Hepatitis B Market and Competitive Landscape Highlights - 2019, provides comprehensive insights into Hepatitis B pipeline products, Hepatitis B epidemiology, Hepatitis B market valuations and forecast, Hepatitis B drugs sales and competitive landscape in the US.
  • The research is classified into seven sections - Hepatitis B treatment options, pipeline products, market analysis comprising of epidemiology, key products marketed, market valuations and forecast, drugs sales and market shares.
  • Hepatitis B pipeline: Find out the products in clinical trials for the treatment of Hepatitis B by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products
    Hepatitis B drugs: Identify key products marketed and prescribed for Hepatitis B in the US, including trade name, molecule name, and company
    Hepatitis B market valuations: Find out the market size for Hepatitis B drugs in 2018 in the US.
  • Find out how the market advanced from 2014 and forecast to 2024
    Hepatitis B drugs market share: Find out the market shares for key Hepatitis B drugs in the US
    Evaluate commercial market opportunity assessment, positioning, and segmentation for Hepatitis B products

Enzo Biochem Announces Key Transformative Initiatives to Propel and Accelerate Growth In its Lab Business

Retrieved on: 
Thursday, July 11, 2019
Other Science, Research, Pharmaceutical, Oncology, Medical devices, Infectious diseases, Hospitals, Genetics, Science, Clinical trials, Biotechnology, AIDS, Health, RTT, Infectious causes of cancer, Papillomavirus, Carcinogens, Human papillomavirus infection, Health, Medicine, Clinical medicine

Enzo Biochem, Inc. (NYSE: ENZ) today announced several key transformative initiatives in its labs business unit designed to propel and accelerate growth.

Key Points: 
  • Enzo Biochem, Inc. (NYSE: ENZ) today announced several key transformative initiatives in its labs business unit designed to propel and accelerate growth.
  • In 2017, according to CDC, 11 million men and 3.2 million women tested positive for oral HPV infections, underscoring the disproportionate growth in infections among men.
  • With this latest approval, Enzo now provides expanded specimen collection options from multiple relevant body sites for NG and CT testing.
  • We believe this business model and expansion of our product line has significant potential, said Barry Weiner, President and Chief Financial Officer of Enzo.

United States Cervical Cancer Market 2019: Treatment, Pipeline, Epidemiology, Key Products, Valuations, Drug Sales and Market Shares - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 11, 2019
Health, Pharmaceutical, Cancer, RTT, Gynaecological cancer, Infectious causes of cancer, Cervical cancer, Cervical, Epidemiology of cancer

US Cervical Cancer Market and Competitive Landscape Highlights - 2019, provides comprehensive insights into Cervical Cancer pipeline products, Cervical Cancer epidemiology, Cervical Cancer market valuations and forecast, Cervical Cancer drugs sales and competitive landscape in the US.

Key Points: 
  • US Cervical Cancer Market and Competitive Landscape Highlights - 2019, provides comprehensive insights into Cervical Cancer pipeline products, Cervical Cancer epidemiology, Cervical Cancer market valuations and forecast, Cervical Cancer drugs sales and competitive landscape in the US.
  • The research is classified into seven sections- Cervical Cancer treatment options, pipeline products, market analysis comprising of epidemiology, key products marketed, market valuations and forecast, drugs sales and market shares.
  • Cervical Cancer pipeline: Find out the products in clinical trials for the treatment of Cervical Cancer by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products
    Cervical Cancer drugs: Identify key products marketed and prescribed for Cervical Cancer in the US, including trade name, molecule name, and company
    Cervical Cancer market valuations: Find out the market size for Cervical Cancer drugs in 2018 in the US.
  • Find out how the market advanced from 2014 and forecast to 2024
    Cervical Cancer drugs market share: Find out the market shares for key Cervical Cancer drugs in the US
    Evaluate commercial market opportunity assessment, positioning, and segmentation for Cervical Cancer products

Check-Cap Announces Positive Final Results from Its Post-CE Approval Study of the C-Scan® System

Retrieved on: 
Tuesday, July 9, 2019
Infectious causes of cancer, Colorectal cancer, RTT, Polyp, Medicine, Clinical medicine, Health

The study included 90 evaluable patients who either had known polyps or were considered to be of average risk.

Key Points: 
  • The study included 90 evaluable patients who either had known polyps or were considered to be of average risk.
  • C-Scan achieved a specificity of 82% in all patients, while FIT achieved a specificity of 96% in all patients.
  • Alex Ovadia, chief executive officer of Check-Cap, commented, "We are delighted to share the results from the post-CE approval study which continue to validate the importance and potential of the C-Scan system.
  • Assuming positive pilot study results, the Company plans to initiate a pivotal study in people of average risk for polyps and colorectal cancer in mid-2020.

The global alcoholic hepatitis treatment market at a CAGR of close to 6% during the forecast period

Retrieved on: 
Monday, July 8, 2019
Medical specialties, Medicine, Hepatitis, Clinical medicine, RTT, Alcoholic hepatitis, Infectious causes of cancer, Liver disease

Also, our global alcoholic hepatitis treatment market report looks at factors such as the increasing consumption of alcohol worldwide, availability of prognostic models for alcoholic hepatitis, and high market penetration of corticosteroids and off-label therapies.

Key Points: 
  • Also, our global alcoholic hepatitis treatment market report looks at factors such as the increasing consumption of alcohol worldwide, availability of prognostic models for alcoholic hepatitis, and high market penetration of corticosteroids and off-label therapies.
  • However, lack of therapies to treat severe alcoholic hepatitis, side effects associated with drugs used to treat alcoholic hepatitis, and availability of alternative therapies may hamper the growth of the alcoholic hepatitis treatment industry over the forecast period.
  • The increasing demand for these drugs will lead to the expansion of the global alcoholic hepatitis treatment market at a CAGR of close to 6% during the forecast period.
  • For the detailed list of factors that will drive the global alcoholic hepatitis treatment market during the forecast period 2019-2023, click here.

Intent Solutions Joins University of Kentucky Program to Eliminate Hepatitis C in Appalachia

Retrieved on: 
Monday, July 8, 2019
Medical specialties, Infectious diseases, Medicine, Healthcare-associated infections, Infectious causes of cancer, Hepatitis C virus, RTT, Hepatitis C, Viral hepatitis, Hepatitis, Hepacivirus C, Hepacivac

Intent Solutions recently signed a contract with the University of Kentucky to manage the dispensation of hepatitis C medications to 900 individuals in the program and to use its tad dispensing system to track patient adherence to the prescribed drug regimen.

Key Points: 
  • Intent Solutions recently signed a contract with the University of Kentucky to manage the dispensation of hepatitis C medications to 900 individuals in the program and to use its tad dispensing system to track patient adherence to the prescribed drug regimen.
  • The goal of the Kentucky Viral Hepatitis Treatment Study (KeY Treat) is to eliminate the hepatitis C virus (HCV) from Perry County by treating all residents of the county who are chronically infected, especially those at highest risk for transmitting the virus.
  • "tad is uniquely suited to population health intervention programs like this one, and we are proud to be part of it," said Sam Zamarripa, CEO of Intent Solutions.
  • "Prescription adherence is important in any treatment program, but especially so in the 12-week regimen required to rid the body of hepatitis C virus (HCV)," Zamarripa said.

Enanta Pharmaceuticals Initiates Phase 1 Clinical Study of EDP-514, its Lead Core Inhibitor for the Treatment of Hepatitis B Virus (HBV)

Retrieved on: 
Monday, July 8, 2019
Biotechnology, Health, Pharmaceutical, Clinical trials, Chemical compounds, Infectious diseases, Chemistry, Infectious causes of cancer, RTT, Healthcare-associated infections, Viral diseases, Cyclopropanes, Glecaprevir, Hepatitis C, Hepatitis, Hepacivirus C, EDP-514, Hepatitis B Virus, Enanta

The study plans to enroll approximately 98 subjects and to evaluate up to 6 dose cohorts, with EDP-514 administered orally, once daily.

Key Points: 
  • The study plans to enroll approximately 98 subjects and to evaluate up to 6 dose cohorts, with EDP-514 administered orally, once daily.
  • Receipt of Fast Track designation from the FDA emphasizes the large unmet need of patients with chronic HBV infection.
  • EDP-514, a novel class II hepatitis B virus (HBV) core inhibitor, is Enantas lead core inhibitor candidate.
  • Glecaprevir, a protease inhibitor discovered by Enanta, is now sold by AbbVie in numerous countries as part of its newest treatment for chronic hepatitis C virus (HCV) infection.

Alzheimer's Disease Virus Research Spotlighted at HHV-6 Conference, Reports Dr. Leslie Norins of Alzheimer's Germ Quest, Inc.

Retrieved on: 
Monday, July 8, 2019
Viruses, Betaherpesvirinae, Human herpesvirus 6, Infectious causes of cancer, Viral diseases, Herpesviridae, HHV, Immune system disorders, Dharam Ablashi

"It was another sign that microbiological agents, including HHV-6, are finally beginning to receive the increased scrutiny in Alzheimer's disease research they've deserved for many years," says Dr. Norins.

Key Points: 
  • "It was another sign that microbiological agents, including HHV-6, are finally beginning to receive the increased scrutiny in Alzheimer's disease research they've deserved for many years," says Dr. Norins.
  • He adds, "The entire spectrum of HHV-6 and its relatives' involvement in other 'mystery illnesses' is also intriguing".
  • He credits the HHV-6 Foundation, and its co-founder/executive director, Kristin Loomis, with helping to maintain interest in this group of herpesviruses.
  • Sinai, New York), who reviewed his research on HHV-6 in Alzheimer's brains, co-authored by Dr. Ben Readhead (Arizona State University) and several others.

Alzheimer's disease virus research spotlighted at HHV-6 conference, reports Dr. Leslie Norins of Alzheimer's Germ Quest, Inc.

Retrieved on: 
Monday, July 8, 2019
Viruses, Betaherpesvirinae, Human herpesvirus 6, Infectious causes of cancer, Viral diseases, Herpesviridae, HHV, Immune system disorders, Dharam Ablashi

"It was another sign that microbiological agents, including HHV-6, are finally beginning to receive the increased scrutiny in Alzheimer's disease research they've deserved for many years," says Dr. Norins.

Key Points: 
  • "It was another sign that microbiological agents, including HHV-6, are finally beginning to receive the increased scrutiny in Alzheimer's disease research they've deserved for many years," says Dr. Norins.
  • He adds, "The entire spectrum of HHV-6 and its relatives' involvement in other 'mystery illnesses' is also intriguing."
  • He credits the HHV-6 Foundation , and its co-founder/executive director, Kristin Loomis, with helping to maintain interest in this group of herpesviruses.
  • Sinai, New York), who reviewed his research on HHV-6 in Alzheimer's brains, co-authored by Dr. Ben Readhead (Arizona State University) and several others.

US Cervical Dysplasia Market and Competitive Landscape, 2019 - ResearchAndMarkets.com

Retrieved on: 
Friday, July 5, 2019
Pharmaceutical, Health, Oncology, Infectious causes of cancer, Oncology, Histopathology, Medicine, Medical specialties, Dysplasia, Health, Cervical intraepithelial neoplasia, RTT

The "US Cervical Dysplasia Market and Competitive Landscape - 2019" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US Cervical Dysplasia Market and Competitive Landscape - 2019" report has been added to ResearchAndMarkets.com's offering.
  • The latest research, US Cervical Dysplasia Market and Competitive Landscape Highlights - 2019, provides comprehensive insights into Cervical Dysplasia pipeline products, Cervical Dysplasia epidemiology, Cervical Dysplasia market valuations and forecast, Cervical Dysplasia drugs sales and competitive landscape in the US.
  • Cervical Dysplasia pipeline: Find out the products in clinical trials for the treatment of Cervical Dysplasia by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products
    Cervical Dysplasia drugs: Identify key products marketed and prescribed for Cervical Dysplasia in the US, including trade name, molecule name, and company
    Cervical Dysplasia market valuations: Find out the market size for Cervical Dysplasia drugs in 2018 in the US.
  • Find out how the market advanced from 2014 and forecast to 2024
    Cervical Dysplasia drugs market share: Find out the market shares for key Cervical Dysplasia drugs in the US
    Evaluate commercial market opportunity assessment, positioning, and segmentation for Cervical Dysplasia products